Followers | 273 |
Posts | 55399 |
Boards Moderated | 23 |
Alias Born | 08/29/2007 |
Thursday, April 04, 2024 7:24:25 AM
https://ih.advfn.com/markets/nasdaq/premarket
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent TVGN News
- Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation • GlobeNewswire Inc. • 09/24/2024 03:09:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/26/2024 08:10:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/26/2024 08:05:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/23/2024 09:04:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:02:28 PM
- Tevogen Bio Secures $6 Million Series C Preferred Stock Investment • GlobeNewswire Inc. • 08/22/2024 01:00:00 PM
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares • GlobeNewswire Inc. • 08/15/2024 04:17:01 PM
- Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares • GlobeNewswire Inc. • 08/15/2024 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/14/2024 08:40:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:38:58 PM
- Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health • GlobeNewswire Inc. • 08/14/2024 01:00:00 PM
- Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities • GlobeNewswire Inc. • 08/09/2024 03:00:00 PM
- Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback • GlobeNewswire Inc. • 07/11/2024 04:21:21 PM
- Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian • GlobeNewswire Inc. • 07/10/2024 12:05:00 PM
- Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility • GlobeNewswire Inc. • 07/08/2024 08:07:16 PM
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities • GlobeNewswire Inc. • 06/26/2024 04:46:13 PM
- Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances • GlobeNewswire Inc. • 06/25/2024 12:05:00 PM
- Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference • GlobeNewswire Inc. • 06/18/2024 07:17:05 PM
- Tevogen Bio Set to Join Russell 3000® Index • GlobeNewswire Inc. • 06/12/2024 07:45:00 PM
- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts • GlobeNewswire Inc. • 06/11/2024 07:30:00 PM
- CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event • GlobeNewswire Inc. • 06/07/2024 07:32:04 PM
- Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event • GlobeNewswire Inc. • 06/06/2024 10:14:31 PM
- Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 • GlobeNewswire Inc. • 06/06/2024 07:52:26 PM
- Tevogen Bio Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives • GlobeNewswire Inc. • 05/16/2024 06:00:00 PM
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM